184 related articles for article (PubMed ID: 35884425)
1. Uncovering the Contribution of Moderate-Penetrance Susceptibility Genes to Breast Cancer by Whole-Exome Sequencing and Targeted Enrichment Sequencing of Candidate Genes in Women of European Ancestry.
Dumont M; Weber-Lassalle N; Joly-Beauparlant C; Ernst C; Droit A; Feng BJ; Dubois S; Collin-Deschesnes AC; Soucy P; Vallée M; Fournier F; Lemaçon A; Adank MA; Allen J; Altmüller J; Arnold N; Ausems MGEM; Berutti R; Bolla MK; Bull S; Carvalho S; Cornelissen S; Dufault MR; Dunning AM; Engel C; Gehrig A; Geurts-Giele WRR; Gieger C; Green J; Hackmann K; Helmy M; Hentschel J; Hogervorst FBL; Hollestelle A; Hooning MJ; Horváth J; Ikram MA; Kaulfuß S; Keeman R; Kuang D; Luccarini C; Maier W; Martens JWM; Niederacher D; Nürnberg P; Ott CE; Peters A; Pharoah PDP; Ramirez A; Ramser J; Riedel-Heller S; Schmidt G; Shah M; Scherer M; Stäbler A; Strom TM; Sutter C; Thiele H; van Asperen CJ; van der Kolk L; van der Luijt RB; Volk AE; Wagner M; Waisfisz Q; Wang Q; Wang-Gohrke S; Weber BHF; Genome Of The Netherlands Project ; Ghs Study Group ; Devilee P; Tavtigian S; Bader GD; Meindl A; Goldgar DE; Andrulis IL; Schmutzler RK; Easton DF; Schmidt MK; Hahnen E; Simard J
Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884425
[TBL] [Abstract][Full Text] [Related]
2. Identification of candidate cancer predisposing variants by performing whole-exome sequencing on index patients from BRCA1 and BRCA2-negative breast cancer families.
Shahi RB; De Brakeleer S; Caljon B; Pauwels I; Bonduelle M; Joris S; Fontaine C; Vanhoeij M; Van Dooren S; Teugels E; De Grève J
BMC Cancer; 2019 Apr; 19(1):313. PubMed ID: 30947698
[TBL] [Abstract][Full Text] [Related]
3. Whole exome sequencing suggests much of non-BRCA1/BRCA2 familial breast cancer is due to moderate and low penetrance susceptibility alleles.
Gracia-Aznarez FJ; Fernandez V; Pita G; Peterlongo P; Dominguez O; de la Hoya M; Duran M; Osorio A; Moreno L; Gonzalez-Neira A; Rosa-Rosa JM; Sinilnikova O; Mazoyer S; Hopper J; Lazaro C; Southey M; Odefrey F; Manoukian S; Catucci I; Caldes T; Lynch HT; Hilbers FS; van Asperen CJ; Vasen HF; Goldgar D; Radice P; Devilee P; Benitez J
PLoS One; 2013; 8(2):e55681. PubMed ID: 23409019
[TBL] [Abstract][Full Text] [Related]
4. Pathogenic and likely pathogenic variants in PALB2, CHEK2, and other known breast cancer susceptibility genes among 1054 BRCA-negative Hispanics with breast cancer.
Weitzel JN; Neuhausen SL; Adamson A; Tao S; Ricker C; Maoz A; Rosenblatt M; Nehoray B; Sand S; Steele L; Unzeitig G; Feldman N; Blanco AM; Hu D; Huntsman S; Castillo D; Haiman C; Slavin T; Ziv E
Cancer; 2019 Aug; 125(16):2829-2836. PubMed ID: 31206626
[TBL] [Abstract][Full Text] [Related]
5. Analysis of rare disruptive germline mutations in 2135 enriched BRCA-negative breast cancers excludes additional high-impact susceptibility genes.
Loveday C; Garrett A; Law P; Hanks S; Poyastro-Pearson E; Adlard JW; Barwell J; Berg J; Brady AF; Brewer C; Chapman C; Cook J; Davidson R; Donaldson A; Douglas F; Greenhalgh L; Henderson A; Izatt L; Kumar A; Lalloo F; Miedzybrodzka Z; Morrison PJ; Paterson J; Porteous M; Rogers MT; Walker L; ; Eccles D; Evans DG; Snape K; Hanson H; Houlston RS; Turnbull C
Ann Oncol; 2022 Dec; 33(12):1318-1327. PubMed ID: 36122798
[TBL] [Abstract][Full Text] [Related]
6. Whole exome sequencing and replication for breast cancer among Hispanic/Latino women identifies
Nierenberg JL; Adamson AW; Hu D; Huntsman S; Patrick C; Li M; Steele L; Tong B; Shieh Y; Fejerman L; Gruber SB; Haiman CA; John EM; Kushi LH; Torres-Mejía G; Ricker C; Weitzel JN; Ziv E; Neuhausen SL
medRxiv; 2023 Jan; ():. PubMed ID: 36747679
[TBL] [Abstract][Full Text] [Related]
7. Association of a Polygenic Risk Score With Breast Cancer Among Women Carriers of High- and Moderate-Risk Breast Cancer Genes.
Gallagher S; Hughes E; Wagner S; Tshiaba P; Rosenthal E; Roa BB; Kurian AW; Domchek SM; Garber J; Lancaster J; Weitzel JN; Gutin A; Lanchbury JS; Robson M
JAMA Netw Open; 2020 Jul; 3(7):e208501. PubMed ID: 32609350
[TBL] [Abstract][Full Text] [Related]
8. Exome sequencing identifies breast cancer susceptibility genes and defines the contribution of coding variants to breast cancer risk.
Wilcox N; Dumont M; González-Neira A; Carvalho S; Joly Beauparlant C; Crotti M; Luccarini C; Soucy P; Dubois S; Nuñez-Torres R; Pita G; Gardner EJ; Dennis J; Alonso MR; Álvarez N; Baynes C; Collin-Deschesnes AC; Desjardins S; Becher H; Behrens S; Bolla MK; Castelao JE; Chang-Claude J; Cornelissen S; Dörk T; Engel C; Gago-Dominguez M; Guénel P; Hadjisavvas A; Hahnen E; Hartman M; Herráez B; ; Jung A; Keeman R; Kiechle M; Li J; Loizidou MA; Lush M; Michailidou K; Panayiotidis MI; Sim X; Teo SH; Tyrer JP; van der Kolk LE; Wahlström C; Wang Q; Perry JRB; Benitez J; Schmidt MK; Schmutzler RK; Pharoah PDP; Droit A; Dunning AM; Kvist A; Devilee P; Easton DF; Simard J
Nat Genet; 2023 Sep; 55(9):1435-1439. PubMed ID: 37592023
[TBL] [Abstract][Full Text] [Related]
9. Multi-gene panel testing and association analysis in Cypriot breast cancer cases and controls.
Zanti M; Loizidou MA; O'Mahony DG; Dorling L; Dennis J; Devilee P; Easton DF; Panayiotidis MI; Hadjisavvas A; Michailidou K
Front Genet; 2023; 14():1248492. PubMed ID: 37790698
[No Abstract] [Full Text] [Related]
10. Breast cancer risks associated with missense variants in breast cancer susceptibility genes.
Dorling L; Carvalho S; Allen J; Parsons MT; Fortuno C; González-Neira A; Heijl SM; Adank MA; Ahearn TU; Andrulis IL; Auvinen P; Becher H; Beckmann MW; Behrens S; Bermisheva M; Bogdanova NV; Bojesen SE; Bolla MK; Bremer M; Briceno I; Camp NJ; Campbell A; Castelao JE; Chang-Claude J; Chanock SJ; Chenevix-Trench G; ; Collée JM; Czene K; Dennis J; Dörk T; Eriksson M; Evans DG; Fasching PA; Figueroa J; Flyger H; Gabrielson M; Gago-Dominguez M; García-Closas M; Giles GG; Glendon G; Guénel P; Gündert M; Hadjisavvas A; Hahnen E; Hall P; Hamann U; Harkness EF; Hartman M; Hogervorst FBL; Hollestelle A; Hoppe R; Howell A; ; ; Jakubowska A; Jung A; Khusnutdinova E; Kim SW; Ko YD; Kristensen VN; Lakeman IMM; Li J; Lindblom A; Loizidou MA; Lophatananon A; Lubiński J; Luccarini C; Madsen MJ; Mannermaa A; Manoochehri M; Margolin S; Mavroudis D; Milne RL; Mohd Taib NA; Muir K; Nevanlinna H; Newman WG; Oosterwijk JC; Park SK; Peterlongo P; Radice P; Saloustros E; Sawyer EJ; Schmutzler RK; Shah M; Sim X; Southey MC; Surowy H; Suvanto M; Tomlinson I; Torres D; Truong T; van Asperen CJ; Waltes R; Wang Q; Yang XR; Pharoah PDP; Schmidt MK; Benitez J; Vroling B; Dunning AM; Teo SH; Kvist A; de la Hoya M; Devilee P; Spurdle AB; Vreeswijk MPG; Easton DF
Genome Med; 2022 May; 14(1):51. PubMed ID: 35585550
[TBL] [Abstract][Full Text] [Related]
11. Familial breast cancer and DNA repair genes: Insights into known and novel susceptibility genes from the GENESIS study, and implications for multigene panel testing.
Girard E; Eon-Marchais S; Olaso R; Renault AL; Damiola F; Dondon MG; Barjhoux L; Goidin D; Meyer V; Le Gal D; Beauvallet J; Mebirouk N; Lonjou C; Coignard J; Marcou M; Cavaciuti E; Baulard C; Bihoreau MT; Cohen-Haguenauer O; Leroux D; Penet C; Fert-Ferrer S; Colas C; Frebourg T; Eisinger F; Adenis C; Fajac A; Gladieff L; Tinat J; Floquet A; Chiesa J; Giraud S; Mortemousque I; Soubrier F; Audebert-Bellanger S; Limacher JM; Lasset C; Lejeune-Dumoulin S; Dreyfus H; Bignon YJ; Longy M; Pujol P; Venat-Bouvet L; Bonadona V; Berthet P; Luporsi E; Maugard CM; Noguès C; Delnatte C; Fricker JP; Gesta P; Faivre L; Lortholary A; Buecher B; Caron O; Gauthier-Villars M; Coupier I; Servant N; Boland A; Mazoyer S; Deleuze JF; Stoppa-Lyonnet D; Andrieu N; Lesueur F
Int J Cancer; 2019 Apr; 144(8):1962-1974. PubMed ID: 30303537
[TBL] [Abstract][Full Text] [Related]
12. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
[TBL] [Abstract][Full Text] [Related]
13. Moderate penetrance genes complicate genetic testing for breast cancer diagnosis: ATM, CHEK2, BARD1 and RAD51D.
Graffeo R; Rana HQ; Conforti F; Bonanni B; Cardoso MJ; Paluch-Shimon S; Pagani O; Goldhirsch A; Partridge AH; Lambertini M; Garber JE
Breast; 2022 Oct; 65():32-40. PubMed ID: 35772246
[TBL] [Abstract][Full Text] [Related]
14. Evaluating the breast cancer predisposition role of rare variants in genes associated with low-penetrance breast cancer risk SNPs.
Li N; Rowley SM; Thompson ER; McInerny S; Devereux L; Amarasinghe KC; Zethoven M; Lupat R; Goode D; Li J; Trainer AH; Gorringe KL; James PA; Campbell IG
Breast Cancer Res; 2018 Jan; 20(1):3. PubMed ID: 29316957
[TBL] [Abstract][Full Text] [Related]
15. Frequency of pathogenic germline variants in BRCA1, BRCA2, PALB2, CHEK2 and TP53 in ductal carcinoma in situ diagnosed in women under the age of 50 years.
Petridis C; Arora I; Shah V; Megalios A; Moss C; Mera A; Clifford A; Gillett C; Pinder SE; Tomlinson I; Roylance R; Simpson MA; Sawyer EJ
Breast Cancer Res; 2019 May; 21(1):58. PubMed ID: 31060593
[TBL] [Abstract][Full Text] [Related]
16. The Contribution of Germline Pathogenic Variants in Breast Cancer Genes to Contralateral Breast Cancer Risk in
Larionov A; Fewings E; Redman J; Goldgraben M; Clark G; Boice J; Concannon P; Bernstein J; Conti DV; The Wecare Study Collaborative Group ; Tischkowitz M
Cancers (Basel); 2023 Jan; 15(2):. PubMed ID: 36672364
[TBL] [Abstract][Full Text] [Related]
17. Whole-exome sequencing and targeted gene sequencing provide insights into the role of PALB2 as a male breast cancer susceptibility gene.
Silvestri V; Zelli V; Valentini V; Rizzolo P; Navazio AS; Coppa A; Agata S; Oliani C; Barana D; Castrignanò T; Viel A; Russo A; Tibiletti MG; Zanna I; Masala G; Cortesi L; Manoukian S; Azzollini J; Peissel B; Bonanni B; Peterlongo P; Radice P; Palli D; Giannini G; Chillemi G; Montagna M; Ottini L
Cancer; 2017 Jan; 123(2):210-218. PubMed ID: 27648926
[TBL] [Abstract][Full Text] [Related]
18. Characterization of genetic predisposition to molecular subtypes of breast cancer in Brazilian patients.
Paixão D; Torrezan GT; Santiago KM; Formiga MN; Ahuno ST; Dias-Neto E; Tojal da Silva I; Foulkes WD; Polak P; Carraro DM
Front Oncol; 2022; 12():976959. PubMed ID: 36119527
[TBL] [Abstract][Full Text] [Related]
19. Rare, evolutionarily unlikely missense substitutions in CHEK2 contribute to breast cancer susceptibility: results from a breast cancer family registry case-control mutation-screening study.
Le Calvez-Kelm F; Lesueur F; Damiola F; Vallée M; Voegele C; Babikyan D; Durand G; Forey N; McKay-Chopin S; Robinot N; Nguyen-Dumont T; Thomas A; Byrnes GB; ; Hopper JL; Southey MC; Andrulis IL; John EM; Tavtigian SV
Breast Cancer Res; 2011 Jan; 13(1):R6. PubMed ID: 21244692
[TBL] [Abstract][Full Text] [Related]
20. The contribution of pathogenic variants in breast cancer susceptibility genes to familial breast cancer risk.
Slavin TP; Maxwell KN; Lilyquist J; Vijai J; Neuhausen SL; Hart SN; Ravichandran V; Thomas T; Maria A; Villano D; Schrader KA; Moore R; Hu C; Wubbenhorst B; Wenz BM; D'Andrea K; Robson ME; Peterlongo P; Bonanni B; Ford JM; Garber JE; Domchek SM; Szabo C; Offit K; Nathanson KL; Weitzel JN; Couch FJ
NPJ Breast Cancer; 2017; 3():22. PubMed ID: 28649662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
